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We describe the first case of Neisseria meningitidis
W135 meningitis in Turkey. The strain was genotypically
unrelated to the clone (W)ET-37, isolated from Hajj pilgrims
in 2000.
The Case
A previously healthy 20-year-old serviceman experi-
enced chills, headache, and vomiting 2 days before being
admitted to the hospital in March 2003. On physical exam-
ination, neck stiffness, Kernig sign, Brudzinski sign, and
temperature of 40°C were noted. The patient’s cere-
brospinal fluid (CSF) was turbid with increased protein
and pressure; leukocyte count was 4,500/µL. CSF culture
grew Neisseria meningitidis in 24 hours. The strain was
serogrouped as W135 by specific antiserum (Difco,
Sparks, MD) in Hacettepe Medical School, Turkey, and
confirmed by the Centers for Disease Control and
Prevention (CDC, Atlanta, GA). Blood culture results were
negative, and the patient had no petechial rash. He was
treated with high-dose cefotaxime (3 g every 6 hours for
14 days) and made a full recovery.
For this isolate, both disk-diffusion and E-test methods
using cefotaxime, penicillin, tetracycline, and ciprofloxacin
were performed according to the criteria defined by the
British Society for Antimicrobial Chemotherapy (1,2).
Both methods were performed on Iso-Sensitest agar
(Oxoid, Basingstoke, UK), supplemented with 5% defibri-
nated horse blood and nicotine adenine dinucleotide
(Sigma, Taufkrichen, Germany). The isolate was suscepti-
ble to all of the antimicrobial agents (Table). The service-
man did not attend the Hajj and had no history of travel or
contact with returning pilgrims.
Conclusions
To the best of our knowledge, N. meningitidis W135
meningococcal disease has never been reported in Turkey.
One W135 isolate from an asymptomatic carrier was
reported in a child in 2001 (3). Globally, W135 strains are
often isolated after intensive vaccination campaigns
against serogroup Aand C meningococci have been imple-
mented (4). This patient’s vaccination certificate con-
firmed that he had received a bivalent (A+C)
meningococcal vaccine 2 months earlier, at the beginning
of his military training period. Turkish military vaccination
campaigns have used the A+C polysaccharide vaccine suc-
cessfully for a decade.
Multilocus enzyme electrophoresis, pulsed-field gel
electrophoresis (PFGE), multilocus sequence typing, mul-
tilocus DNA fragment typing, and sequencing the 16S
rRNA gene are new genotypic approaches to characterize
N. meningitidis strains (5). This isolate was genotyped by
using PFGE and 16S sequencing at CDC; both methods
showed that it was a different subtype than the one associ-
ated with the Hajj pilgrimage in 2000 and 2001 (Figure).
In Turkey, most of the population is Muslim, and
approximately 150,000 pilgrims travel annually to Saudi
Arabia for the Hajj. During the pilgrimage in 2000 and
2001, an international outbreak was caused by a previous-
ly rare meningococcal serogroup W135 clone, (W)ET-37,
possibly because conditions during the pilgrimage facili-
tate person-to-person transmission of meningococci (6,7).
For the Hajj season of 2002 and 2003, all Turkish pilgrims
received a quadrivalent meningococcal polysaccharide
vaccine (Mencewax ACWY, SmithKline Beecham,
Genval, Belgium). Although the quadrivalent meningococ-
cal vaccine can protect persons against disease attributable
to W135, it does not prevent them from becoming asymp-
tomatic carriers, and therefore the vaccine may not prevent
transmission to unvaccinated household contacts (7,8).
A recent study in the United States (9) showed that
0.8% of 727 returning pilgrims in 2001 were W135 carri-
ers, although none had been on departure. To our knowl-
edge, the rate of pilgrims returning to Turkey as W135
carriers has not been studied. On the basis of W135 trans-
mission rates and epidemiologic data, we estimated the
risk of an unvaccinated contact who had acquired W135
developing invasive meningococcal disease to be 1 case
per 70 infections (7). In Singapore, disease usually devel-
oped within 14 days of a person’s contact with Hajj pil-
grims, and no cases occurred 2 months after the end of Hajj
pilgrimages (7). In Mauritius, a small tropical island in the
Indian Ocean, one case of meningococcal disease caused
by W135 occurred in a girl 3 months after her father
returned from the Hajj pilgrimage; however, the virus
could not be cultured, and it was not shown to be related to
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Table. Susceptibility testing results of the isolate by E-test and 
disk-diffusion method 
Antimicrobial agent tested  MIC (µg/mL)  Zone diameter (mm) 
Penicillin  0.050  30 
Cefotaxime  0.016  30 
Tetracycline  1.000  23 
Ciprofloxacin  0.002  32 the Hajj strains (10). The case we report here occurred
approximately 50 days after most Turkish pilgrims
returned, which suggests that it was unrelated to the Hajj. 
Although our patient had no history of travel or contact
with a returning pilgrim, we investigated possible associa-
tions with the Hajj. However, PFGE results indicated that
our patient’s strain was not closely related to the (W)ET-37
clone associated with the Hajj and may be unique to
Turkey. Similarly, Jolley et al. from the Czech Republic
have also reported sequence types of W135 other than
(W)ET-37 (11). Additional investigation will be required
to produce a database of well-documented Turkish cases.
After the outbreaks in 2000 and 2001, many European
countries reported additional cases of W135 meningitis in
persons with no history of pilgrimage or contact with a
returning pilgrim. 
Since quadrivalent meningococcal vaccine does not
prevent asymptomatic infection and therefore may not pre-
vent returning pilgrims from transmitting W135 to unvac-
cinated household contacts, prophylactically administering
antimicrobial agents should be considered to reduce the
risk for transmission. Any decision to administer chemo-
prophylaxis to all returning pilgrims should depend on the
rate of transmission of W135 infection from asymptomatic
carriers to contacts after future pilgrimages. This case also
showed the continuing need for administering quadrivalent
meningococcal vaccine in the community. W135 meningo-
coccal disease appears to be an emerging problem that
should be investigated epidemiologically. This case con-
firmed the need to further study meningococcal carriers in
order to build a national database and help make decisions
on prophylaxis.
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Figure. PFGE images of the case isolate (top) and the clone ET-
37 (bottom). 
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